×
×

Press Releases

New One-Dose Adjuvant Saves Time, Cost by Removing Need for Booster Shots

  • by
  • Oct 30, 2019

New One-Dose Adjuvant Saves Time, Cost by Removing Need for Booster Shots

WORTHINGTON, Minn. (Oct. 30, 2019) — Newport Laboratories, Inc., a leader in custom-made vaccines, today launches Bio One™, a new, proprietary one-dose adjuvant that helps reduce time, labor and expense by removing the need for booster shots.


Adjuvants: The Biggest Variable in a Vaccine

  • by
  • Jul 19, 2019

There are two basic ingredients in killed vaccines: antigens and adjuvants. While antigens are well understood, there’s far less understanding of the critical role adjuvants play in vaccines’ ability to do their job. But not all adjuvants are the same, and identifying which adjuvant has the right properties to help solve a herd’s health challenges can give producers and veterinarians peace of mind that they’re giving the best possible vaccine to their animals.


Pinkeye: New Challenges Call for New Solutions

  • by
  • May 21, 2019

Cattle herds exposed to infectious bovine keratoconjunctivitis, more commonly known as pinkeye, are at risk of lower calf-growth rate, potential blindness and permanent damage if left untreated.1 It’s estimated that pinkeye causes annual losses of more than $150 million in the United States, affecting over 10 million calves.

With an emerging species of pinkeye bacteria overtaking the previously predominant species, controlling this increasingly complex disease is challenging for many producers and veterinarians. But there are tools that can help.


3 Key Advancements in the Fight Against Strep

  • by
  • Apr 19, 2019

As producers continue to reduce the amount of antibiotics given to their herds, many are looking to other options to fight Streptococcus suis, more commonly known as Strep suis

The pathogen is one of the primary causes of bacterial meningitis in pigs,1 and can cause illness at any stage of production, with associated mortality rates of up to 20 percent.2 With infections often existing subclinically and nearly 100 percent of pigs serving as carriers of the bacteria,3Strep suis is a key concern for many producers. 


Newport Laboratories is now part of Boehringer Ingelheim

  • by
  • Jun 12, 2018

DULUTH, Ga. — [June 12, 2018]

Boehringer Ingelheim (BI) is excited to announce that Newport Laboratories, Inc. in Worthington, Minnesota, is officially part of Boehringer Ingelheim’s animal health business unit.

Newport Laboratories enhances the service and product offerings for BI customers. By providing cutting-edge diagnostics like whole genome sequencing, metagenomics, and bioinformatics, Newport Laboratories crafts custom, autogenous vaccines that target the specific viruses or bacteria causing disease in individual livestock operations.


Randy Shirbroun talks pathology and prevention of diseases

  • by
  • Jun 24, 2016

WORTHINGTON, Minn. – Veterinarian Randy Shirbroun of Newport Laboratories Inc. addressed more than 200 bison producers regarding the pathology and prevention of diseases caused by Mycoplasma bovis. The producers had gathered for the 2016 National Bison Association Summer Conference held in June at Elk River, Minnesota. Shirbroun specializes in ruminant health issues including those seen in the American bison, which became the official U.S. national mammal in May.


Newport Laboratories releases new Mycoplasma bovis Test

  • by
  • Nov 09, 2015

Newport Laboratories, Inc. has developed a new multilocus sequence typing (MLST) technique for Mycoplasma bovis, a significant cause of disease in cattle. The new technology represents a major advancement over the previous diagnostic process and will provide increased resolution and a better assessment of genetic variation that may be associated with antigenic, or strain differences. 

This technological advancement utilizing molecular biology is yet another development to come from Newport Laboratories, Inc., a leader in cutting edge diagnostic technology and the manufacturer of autogenous, or custom-made vaccines.  The new MLST technique evaluates 10 variable genes associated with specific Mycoplasma bovis virulence factors, including several of the variable surface proteins (VSPs).


Announcing TS6 Adjuvant Technology for Custom Made SIV Vaccines

  • by
  • Feb 01, 2014

Newport Laboratories is excited to announce that Custom Made SIV Vaccines are now available with TS6 adjuvant technology developed by Merial. This is the same adjuvant that is found in CIRCOVAC® PCV2 vaccine. Newport Laboratories’ Custom Made Vaccines are made from herd-specific pathogens and represent the disease strains circulating in your herd. Our Custom Made Vaccines utilize PINPOINT® diagnostic and production technologies to create a vaccine targeting your specific needs.


Newport Laboratories launches ParaSail

  • by
  • Mar 07, 2012
ParaSail

WORTHINGTON, MN - Newport Laboratories is excited to announce the arrival of ParaSail®, the swine industry's first avirulent live, single-dose vaccine for Haemophilus parasuis.

Available exclusively through veterinarians, ParaSail has been proven to protect against three of the most predominant strains of H. parasuis currently circulating: serotype 4 (found in 25% of cases), serotype 5 (found in 15% of all cases) and serotype 13. Multiple side-by-side comparisons have showed a single dose of the vaccine to be as effective as a two-dose regime. The USDA has approved ParaSail for use as a single-dose product with a 1mL dose size, intramuscular.